<div id="readability-page-1">386567 09: A television reporter explains the drop in the (Photo by Spencer Platt/Newsmakers) Getty Images Stocks rarely double because of a single headline or lucky timing. They double when the market is anchored to an outdated narrative while fundamentals quietly improve. By the time the story feels obvious, most of the upside is gone.  Looking toward 2026, three companies stand out as credible candidates for that kind of re-rating: Primoris Services, Lyft, and Incyte. Each operates in a different sector, but all share a similar setup: improving economics, identifiable catalysts, and valuations that still reflect skepticism rather than confidence.  None are without risk. But each has a plausible path to doubling if execution continues.  Primoris is not a headline stock, and that is exactly why it remains underappreciated. The company builds and maintains essential infrastructure across energy, power, utilities, and communications. These are long-cycle projects tied to secular investment themes such as grid modernization, energy transition, and broadband expansion.  What has changed is the quality of the business. Management has focused on higher-margin projects, improved contract structures, and disciplined bidding. The result is a backlog that is not only sizable, but increasingly profitable and predictable. Earnings power today is materially stronger than it was just a few years ago.  MORE FOR YOU The doubling case for 2026 is driven less by explosive growth and more by re-rating. If Primoris continues delivering steady earnings growth with improving returns on capital, investors may stop valuing it as a cyclical contractor and start treating it as a strategic infrastructure operator.  That distinction matters. Infrastructure businesses with visible backlog and durable cash flows often trade at meaningfully higher multiples once the market gains confidence in execution.  The risk is execution. Large projects can be unforgiving, and cost inflation or delays can pressure margins. But if Primoris maintains discipline, the upside may come simply from investors recognizing how much the business has already improved.  Lyft spent years being defined by what it was not: not Uber, not profitable, not global. That narrative is increasingly outdated.  Recent results show improving unit economics, stronger take rates, and disciplined cost control. As fixed costs stabilize, incremental revenue increasingly flows to the bottom line. This is the operating leverage investors look for in platform businesses.  The wildcard for 2026 is autonomous driving. Lyft has chosen a partnership-based approach rather than building capital-intensive self-driving technology. If autonomous supply expands through partnerships while Lyft maintains its marketplace role, margins could improve meaningfully without heavy capital investment.  A consistently profitable Lyft with credible exposure to autonomy is a very different stock than the one investors discounted for years. If that perception changes, valuation expansion alone could drive significant upside.  The risks remain competitive pricing pressure and regulatory uncertainty. But Lyft no longer needs perfection. It only needs steady progress.  Close-up of logo for ridesharing service Lyft on a tent, with text reading Apply to Drive Today, Lafayette, California, March 28, 2019. (Photo by Smith Collection/Gado/Getty Images) Getty Images Incyte has long been viewed through a narrow lens, with investor focus centered on Jakafi, its blockbuster treatment for myelofibrosis. That concentration created understandable caution. It also obscured what Incyte has quietly become: a diversified oncology and immunology platform with multiple shots on goal.  Jakafi continues to generate substantial cash flow, funding research and development without balance-sheet strain. Meanwhile, Incyte’s late-stage pipeline spans hematology, solid tumors, and inflammatory diseases, creating meaningful upside optionality over the next several years.  The 2026 doubling thesis rests on perception shift. If even one or two pipeline assets achieve regulatory approval and commercial traction, the market could quickly re-rate Incyte from a mature biotech to a multi-product growth company.  The risks are inherent to biotech: clinical trial setbacks and regulatory delays. But unlike early-stage peers, Incyte’s existing cash flows provide time and flexibility, reducing downside while preserving upside.  Primoris, Lyft, and Incyte are all emerging from periods when the market underestimated their adaptability. If 2026 becomes the year fundamentals fully assert themselves, each has a credible path to doubling.  The opportunity is not about prediction. It is about recognizing when the story has already started to change.</div>

Primoris服务

因塞特医疗

LYFT

<p>Primoris、LYFT 和因塞特医疗是三只被忽视的股票，可能在 2026 年前翻倍。每家公司都在经历经济改善、可识别的催化剂和被低估的估值。Primoris 专注于基础设施项目，LYFT 正在提升其单位经济并探索自动驾驶合作伙伴关系，而因塞特医疗则在多元化其肿瘤学和免疫学平台。这些股票翻倍的潜力在于市场认知的变化和战略计划的执行</p>

三只可能在 2026 年翻倍的被忽视股票